Objective: In this study, we investigated the psychiatric comorbid disorders and quality of life issues such as cognitive dysfunction accompanied by cervical dystonia and accompanying patients, and depression-anxiety; we aimed to investigate the effects of Botulinum toxin (BT) applications on these subjects.

Background: Cervical dystonia is a disease table in which the physical symptoms such as abnormal posture, pain and tremor in head-neck as well as accompanying depression, anxiety and anxiety disorders and patients’ quality of life are adversely affected.

Methods: In our study, 30 patients with botulinum toxin screening with primary (idiopathic) cervical dystonia and their relatives. Concomitant cognitive dysfunction, psychiatric comorbid disorders such as depression and anxiety, and quality of life issues were examined. SMMT (Standardised Mini Mental State Examination) in evaluating cognitive function; STAI-I and II (State-Trait Anxiety Inventory), Hospital Anxiety Scale (HAS), Hospital Depression Scale (HDS) in the evaluation of psychiatric comorbid disorders; TWSTRS (Toronto Western Spasmodic Torticollis Scale) in assessing disease activity; CDQ-24 (Craniocervical Dystonia Questionnaire), CDIP-58 (Cervical Dystonia Impact Profile) and SF-36 (Short Form 36) were applied to evaluate the quality of life.

Results: In our study, there was no effect on cognitive functions in patients, increase in psychiatric comorbid disorders such as depression-anxiety, and quality of life were adversely affected in all areas; it was observed that there was no effect on cognitive functions in the patients’ relatives, increase in the normal population in the psychiatric comorbid disorders such as depression-anxiety and adverse effects on energy / vitality, mental health and general health perception of life quality. Improvement in anxiety level, disease activity and overall quality of life scales were observed with BT administration in patients. Significant improvements were observed in cognitive functions, anxiety and SF-36 subscales in energy / vitality and mental health domains after BT administration in patients’ relatives. The benefit seen in BT applications was found to be more evident in women, in married people, in people over 40, in people with higher education levels and in people with late onset (≥ 26 years).

Conclusions: As a result, the increase in the success rate of treatment in the patients will be possible by considering the psychological statements, family and quality of life issues of the patients and following the multidisciplinary approach.

References: 1. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004;( Suppl 8):109-5. 2. Mordin M, Masaqeul C, Abbott C, Copley-Merriman C. (2014) Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxin A (Dysport): results from a randomized, double-blind, placebocontrolled study. BMJ Open 4:005150. 3. Camfield L, Ben-Shlomo Y, Warner TT. Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord 2002;17:838-841. 4. Zurowski M, McDonald WM, Fox S, Marsh L. Psychiatric comorbidities in dystonia: Emerging concepts. Mov. Disord 2013;28:doi.10.1002/mds.25501. 5. Tomic S, Petkovic I, Pucic T, Resan B et al Cervical dystonia and quality of life. Acta Neurol Belg (2016) 116:589–592. 6. Friedman J, Standaert DG. Dystonia and its disorders. Neurol Clin 2001;19:681-705.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/assessment-of-cognitive-functions-depression-anxiety-scales-and-quality-of-life-in-patients-and-their-relatives-with-cervical-dystonia-and-botulinum-toxin-treatment/